| Deal value | $600M |
|---|---|
| Share of market cap | 92.0% |
Key highlights
- $600 million pre-money equity valuation for Alpha AI Biotech Group
- Issuance of 60 million ordinary shares at a fixed price of $10.00 each
- Up to 30 million additional earn-out shares based on post-closing performance
- Consolidated $700,000 convertible note facility with 35% conversion discount
- 30-day limited standstill agreement in place until December 3, 2026
What Is the Deal?
Drugs Made In America Acquisition II Corp., a special purpose acquisition company listed on the Nasdaq, has delivered a preliminary business combination proposal to Alpha AI Biotech Group. The proposed transaction values the target at a pre-money equity valuation of $600 million. Under the terms of the offer, the acquirer would issue 60 million ordinary shares at a fixed price of $10.00 per share to Alpha AI Biotech Group shareholders. The deal remains subject to the completion of due diligence, the negotiation of definitive agreements, and necessary approvals from boards and regulators. A 30-day limited standstill agreement is currently in effect through December 3, 2026.
Deal Structure & Terms
- Pre-money valuation of $600 million satisfied through 60 million ordinary shares
- Earn-out provision for 30 million additional shares in two equal tranches
- First earn-out tier triggered at a $12.50 share price threshold
- Second earn-out tier triggered at a $15.00 share price threshold
- Earn-out period spans 24 months following the closing of the merger
- Standalone 30-day standstill prevents the consummation of competing transactions
Financial Context
The transaction is bolstered by a structured financing arrangement with Tal Alpha Yezum Vekidum Asakim (2003) Ltd. As of early November 2026, the investor has funded $700,000 of a total $1.4 million convertible note facility. This capital has been consolidated into a single promissory note with a maturity date of June 30, 2027. The note features a conversion option allowing the investor to exchange debt for equity in the combined entity at a 35% discount to the prevailing market price. This liquidity provides the necessary runway to finalize the merger while satisfying existing bridge and interim financial obligations.
Industry Landscape
The proposed merger enters an active market for biotech firms leveraging artificial intelligence for drug discovery and development. DMII, currently trading at $10.24, maintains a market capitalization of approximately $652.3 million. The company's technical indicators show a Relative Strength Index of 73.4, suggesting the stock is operating in an overbought zone as market participants react to the merger news. The business combination aligns with the broader sector trend where shell companies target specialized healthcare technology firms to capitalize on the increasing integration of machine learning within pharmaceutical research and high-value clinical pipeline management.
| Share price | $10.24 |
|---|---|
| Market cap | $652M |
| P/E (TTM) | 34.1× |
| 1-month price change | +0.64% |
| Sector | Financial ServicesShell Companies |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Drugs Made In America Acquisition II Corp. announcing a preliminary proposal for a business combination.
Track Drugs Made In America Acquisition II Corp. live
Get the next Drugs Made In America Acquisition II Corp. SEC filing seconds after it lands.



